This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA ETP.PRC GIS XOM IDCC EPR.PRG O.PRF SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP SPG.PRJ HP ORI SPG WPC ADM
THOROFARE, N.J, July 13, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, reports its financial results for the first quarter ended March 31, 2018. A Form 10-Q containing the full financial statements is available for viewing on the Company's website at www.akersbio.com or www.sec.gov.
AKR TMO PHG CAH AKER
Bigger isn’t always better when it comes to dividends. Deutsche Bank recently pointed out “the first half of 2018 has seen the sharpest underperformance of dividend stocks since the financial crisis”, as measured by the Dividend Aristocrats.
DB T TWX CAH TWC WMT
Stocks continue to get more expensive despite the trade war headwinds investors face in the weeks ahead. S&P 500 stocks currently trade at 24 times trailing earnings and 17 times forward earnings making the selection of new additions to a portfolio that much more difficult.
WDC GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG CVS MS.PRA NRGEO NWL GS GLSSP AMZN CAH MS NEE JBK GSC GS.PRICL TFG NYTAB CMI GSJ NEE.PRI GS.PRJ NRG NEE.PRJ GS.PRI MS.PRI MU NEE.PRC GS.PRD MS.PRK GS.PRC NEE.PRQ NEE.PRR GJS GS.PRN GS.PRK
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Putting an end to speculations, Amazon.com, Inc. (AMZN - Free Report) has finally stepped into the high-potential pharmaceutical industry. In line with this, the online retail behemoth recently announced a definitive acquisition agreement with PillPack. Although the terms of the deal have been kept under wraps, a few market experts estimate the value of the transaction at $1 billion.
ABC AMZN RAD MCK WBA CAH CVS AET UNH
The portfolio has underperformed its benchmark so far in 2018, with General Electric being a significant contributor, but it is properly positioned to benefit from several major trends.
FB TWX UAA MET KEY BAC TWTR AAPL ACN INOTF CAH INTC BAC GEC GE C ITT BHGE SYF TWC UA BHI TGT GNE
Stocks were looking for a higher open on Tuesday, with this day being a shortened one ahead of the July 4th holiday. The prior trend of buying the dips has not worked as well in recent months as it had in prior years. Many investors have been considering how they want their investments positioned ahead of the midterm elections and also for the longer term.
MS.PRE MS.PRF MS.PRG CVS UAL MS.PRA AMZN ZFGN CAH MS VNO.PRK VNO.PRL VNO.PRM VNO AAL MS.PRI VRAY MS.PRK ROKU ALV TRI VNO.PRG VNO.PRI WFCNP DB VNO.PRICL ALB MCK VNO.WI WFC.PRL VNORP WFC.PRJ VMW WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN ELOX WFC.PRY WFC.PRX DAL WFC.PRW WFC.PRV WFC VNO.PRH WFC.WS VNO.PRF EPZM AMED MGTX SVOND ABC PEP CVX
Here we are with another installment of my "stock considerations" for the upcoming month. With the first week of trading upon us in July, it is time, once again, to lay out a plan for my potential stock pick(s) for the month. As many of you already know, I make sure to purchase at least one stock every single month, no matter where we are in a business or macroeconomic cycle. The goal of every long-term dividend growth investor is to remain consistent with their buys and try not to attempt to time the market and wait for the "best" possible time to invest.
SOJA HCN PM GIS HCP WELL.PRI LTC SBRA WELL CAH ED JCI SBRAP VTR SO GE GEC D HCN.PRJ KMB HCN.PRI PEP KHC GNE SBUX CLX
9h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Silicon Investor Message Boards
This table lists all message boards related to CAH / Cardinal Health, Inc. on message board site Silicon Investor.
as of ET